{"id":76,"date":"2019-01-05T08:02:55","date_gmt":"2019-01-05T15:02:55","guid":{"rendered":"http:\/\/www.financialstable.com\/?p=76"},"modified":"2019-03-12T04:30:04","modified_gmt":"2019-03-12T11:30:04","slug":"british-fraud-office-abandons-rolls-royce-gsk-investigations","status":"publish","type":"post","link":"https:\/\/www.afinances.com\/2019\/01\/05\/british-fraud-office-abandons-rolls-royce-gsk-investigations\/","title":{"rendered":"British fraud office abandons Rolls-Royce, GSK investigations"},"content":{"rendered":"

The decision, which comes under SFO Director Lisa Osofsky who took the helm last August pledging to review the agency\u2019s caseload, weed out weaker cases and propel others forward, underlines the difficulties of prosecuting senior executives.<\/p>\n

\u201cAfter an extensive and careful examination, I have concluded that there is either insufficient evidence to provide a realistic prospect of conviction or it is not in the public interest to bring a prosecution in these cases,\u201d Osofsky said.<\/p>\n

Rolls-Royce paid almost 500 million pounds ($650 million) under a Deferred Prosecution Agreement (DPA) with the SFO in 2017, drawing a line under a four-year investigation into allegations of criminal conduct spanning three decades, at least seven jurisdictions and three of the company\u2019s business sectors.<\/p>\n

Rolls apologized unreservedly after it was found to have paid bribes including a luxury car and millions of pounds of cash to middlemen to secure orders in countries such as Indonesia, Russia, India, China and Nigeria.<\/p>\n

But a parallel investigation into individuals associated with Rolls-Royce, and the inquiry into GlaxoSmithKline and its subsidiaries, which began in 2014 shortly after the drugs group was fined 3 billion yuan ($447 million) in China for paying bribes to doctors to use its drugs, had made little progress.<\/p>\n

\u201cIt is extraordinary the SFO are unable to charge any individual suspects in relation to Rolls-Royce, given the scale of the allegations in the DPA,\u201d said Sarah Wallace, a partner at law firm Irwin Mitchell.<\/p>\n

HISTORICAL CASES<\/h3>\n

But Wallace added: \u201cIt looks like Osofsky is drawing a line under historical cases and wants to stamp her own mark on new cases going forward.\u201d<\/p>\n

Robert Barrington, a director at anti-corruption group Transparency International, said the decision to drop the Rolls-Royce case could send a message to companies that DPAs were a soft option that give impunity to those who break the law.<\/p>\n

\u201cIt is absurd that yet again a company can admit to bribery and yet neither the bribe payers, nor the management team that allowed the crime to happen, are held responsible,\u201d Barrington said.<\/p>\n

Rolls-Royce said it had noted the decision and declined to comment further. GSK said it was pleased at the SFO decision and that no further action was required.<\/p>\n

The SFO, which faced criticisms of serious failings last year after the collapse of a high-profile retrial of former executives from retailer Tesco, said Osofsky had quietly closed a number of investigations since taking up her post.<\/p>\n

Jonathan Pickworth, a lawyer at White & Case, said she deserved credit for making overdue, tough decisions about longstanding cases.<\/p>\n","protected":false},"excerpt":{"rendered":"

The decision, which comes under SFO Director Lisa Osofsky who took the helm last August pledging to review the agency\u2019s caseload, weed out weaker cases and propel others forward, underlines the difficulties of prosecuting senior executives. \u201cAfter an extensive and careful examination, I have concluded that there is either insufficient evidence to provide a realistic […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[2],"_links":{"self":[{"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/posts\/76"}],"collection":[{"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/comments?post=76"}],"version-history":[{"count":1,"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/posts\/76\/revisions"}],"predecessor-version":[{"id":119,"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/posts\/76\/revisions\/119"}],"wp:attachment":[{"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/media?parent=76"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/categories?post=76"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afinances.com\/wp-json\/wp\/v2\/tags?post=76"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}